Drug intelligence / Profile preview

RT-110

Development stage: Discontinued
Lead developer: RANI Therapeutics
Administration: Oral

Overview

RT-110 is a parathyroid hormone (PTH) replacement therapy developed by Rani Therapeutics for the treatment of hypoparathyroidism. It is classified as a hormone and functions as a parathyroid hormone replacement. The drug was being developed using Rani Therapeutics' oral delivery platform technology, which aims to enable the oral administration of biologic drugs that are typically injectable. As of the latest updates, development for hypoparathyroidism has been suspended or discontinued at the preclinical stage[1][2][3].

Targets

PTH1R (Parathyroid hormone/Parathyroid hormone-related peptide receptor type 1)

Beyond the preview

Go deeper on RT-110.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RT-110.

Explore the full profile